MedTrace Logo

Yliver as a Test to Early Diagnose HCC

NCT03767764 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2021-07-29

No results posted yet for this study

Summary

Liver cancer (HCC) is the second cause of death related to cancer worldwide, with about 750,000 deaths from this cause in 2012. Although the early diagnosis of liver cancer increases the available treatment options, the methods currently used for screening are not sufficiently sensitive for this purpose.

The investigators provide a high-performance and highly reliable in vitro platform that allows the identification and quantification of autoantibodies in serum for use as biomarkers of liver cancer, using an ELISA test (Yliver).

The aim of the study is to demonstrate whether the Yliver test can be used as a biomarker for the early diagnosis of hepatocellular carcinoma with a collection of samples from 58 patients diagnosed with HCC, 42 cirrhosis, 40 normal controls and the inclusion of 25-50 patients with chronic liver disease without cirrhosis.

Conditions

Interventions

DIAGNOSTIC_TEST

Test Yliver

Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique

Sponsors & Collaborators

  • Corporacion Parc Tauli

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-27
Primary Completion
2020-04-01
Completion
2020-09-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03767764 on ClinicalTrials.gov